Genetic mutation linked to Alzheimer’s disease doubles rate of brain tissue loss, USC study shows

October 17, 2013

Thompson_NEJM_2.105257

“Silent time bomb”: Mutation appears to multiply the risk of Alzheimer’s by three or four times

Contact: Alison Trinidad at (323) 442-3941 or alison.trinidad@usc.edu; Suzanne Wu at (213) 740-0252 or suzanne.wu@usc.edu

LOS ANGELES — People who carry a genetic mutation associated with Alzheimer’s disease may develop the disease three years earlier than expected, according to a new study from Keck Medicine of USC.

Scientists at the Keck School of Medicine of USC have mapped the effects of that genetic mutation, showing for the first time how the Alzheimer’s risk factor affects the living human brain. The discovery is detailed in the Oct. 17 edition of The New England Journal of Medicine alongside five other studies focused on the TREM2 gene variant, whose link to Alzheimer’s was first reported in January.

“Our lab studies the rate of brain tissue loss in elderly people, trying to discover factors that protect you as you age,” said Paul M. Thompson, Ph.D., USC professor of neurology, psychiatry, engineering, radiology and ophthalmology and the study’s principal investigator. “We have never seen such a dramatic effect as with this genetic variant. If you carry this genetic mutation, we’ve found that there is this wildfire of tissue loss in the brain.”

Healthy people typically lose less than 1 percent of their brain tissue a year, offset by normal tissue generation from mental stimulation, Thompson said. Symptoms of Alzheimer’s begin to manifest when approximately 10 percent of the brain’s tissue has eroded away.

“This is the first study to use brain scans to show what this gene variant does, and it’s very surprising,” Thompson said. “This gene speeds up brain loss at a terrific pace. Carriers of this genetic mutation, who comprise about 1 percent of the population, lose about 3 percent of their brain tissue per year. This is a silent time bomb in 1 percent of the world.”

Thompson and colleagues compared brain magnetic resonance imaging (MRI) scans of 478 adults (average age 76 years old) participating in the Alzheimer’s Disease Neuroimaging Initiative over two years. The group included 283 men and 195 women from across North America; 100 participants had Alzheimer’s disease, 221 had mild cognitive impairment and 157 were healthy elderly adults.

Keck researchers found that mutation carriers lost 1.4 percent to 3.3 percent more of their brain tissue than non-carriers, and twice as fast. The loss appears to be concentrated in the brain’s temporal lobe and hippocampus, areas that play important roles in memory.

“This TREM2 mutation appears to multiply the risk of Alzheimer’s by three or four times, which is very useful information. Enrolling those people who carry the mutation in clinical trials for Alzheimer’s treatments could help us reach quicker and more meaningful results,” Thompson said.

Co-authors include Priya Rajagopalan, M.B., M.P.H., post-doctoral researcher, and Derrek P. Hibar, Ph.D., assistant professor, at the USC Imaging Genetics Center, which is directed by Thompson. The study was supported by numerous agencies, including the National Institutes of Health (grants U01 AG024904, P30 AG010129, K01 AG030514, EB008281, EB015922, MH097268, NS080655, AG40060, AG016570).

FOR MEDIA: To request a copy of the embargoed paper, press images or an interview with the author, contact Suzanne Wu at suzanne.wu@usc.edu

Image credit: Courtesy Paul M. Thompson: USC scientists show brain tissue loss in carriers of the Alzheimer’s risk gene mutation on MRI at 24 months. The colored areas are the temporal lobes, and the red area is the front of the hippocampus, the area that typically degenerates the earliest if people have Alzheimer’s disease. Areas colored red lose tissue fastest at about 3 percent per year.

Article cited: Rajagopalan, P., Hibar, D.P., & Thompson, P.M. (2013). TREM2 Alzheimer risk gene carriers lose brain tissue faster. The New England Journal of Medicine, 369(16), 156-1567. Published online Oct. 16, 2013; doi:10.1056/NEJMc1306509

ABOUT KECK MEDICINE OF USC

Keck Medicine of USC is the University of Southern California’s medical enterprise, one of only two university-owned academic medical centers in the Los Angeles area. Encompassing academic, research and clinical entities, it consists of the Keck School of Medicine of USC, one of the top medical schools in Southern California; the renowned USC Norris Comprehensive Cancer Center, one of the first comprehensive cancer centers established in the United States; the USC Care faculty practice; the Keck Medical Center of USC, which includes two acute care hospitals: 411-bed Keck Hospital of USC and 60-bed USC Norris Cancer Hospital; and USC Verdugo Hills Hospital, a 158-bed community hospital. It also includes outpatient facilities in Beverly Hills, downtown Los Angeles, La Cañada Flintridge, Pasadena, and the USC University Park campus. USC faculty physicians and Keck School of Medicine departments also have practices throughout Los Angeles, Orange and Riverside counties.